



IBEX Technologies Inc.
5485 Paré, Montréal, Québec, Canada H4P 1P7
Tél : (514) 344-4004 Fax : (514) 344-8827
Website : www.ibex.ca

IBEX REPORTS FIRST QUARTER FISCAL 2009 RESULTS

Sales Increase 10%- Net Profit Increases 78% vs. Previous Quarter

MONTREAL, Quebec, December 9, 2008 – IBEX Technologies Inc. (TSX Venture: IBT), today reported its financial results for the first quarter ended October 31, 2008.

Solely for the convenience of the reader, selected financial results expressed in Canadian dollars on the financial statements, have been translated into U.S. dollars at the October 31, 2008 month-end rate C\$1.00 = US\$ 0.8302. This translation should not be construed as an application of the recommendations relating to the accounting for foreign currency translation, but rather as supplemental information for the reader.

Highlights for the Quarter:

- Sales increased 20% vs. previous quarter and 10% versus year ago
- Net profit increased 78% vs. previous quarter (compares to loss year ago)
- Working capital increased 18% vs. previous quarter

"We are pleased that we continue to increase sales and profitability" said Paul Baehr, IBEX CEO. This quarter marks our fourth consecutive profitable quarter and looking forward, this trend should be positively impacted by the continuing favourable currency climate".

Financial Results for the First Quarter

Sales for the quarter ended October 31, 2008 totaled \$612,430 (US\$508,452) compared to \$554,887 for the same period in the prior year, representing an increase of 10%. Sales increased 20% vs. the previous quarter. Sales of enzymes increased by 48% vs. the previous year, and by 25% vs. the previous quarter, tracing to continued strong demand for the point of care disposables sold by IBEX customers. Sales of arthritis assays decreased 47% vs. year ago, but increased 10% vs. the previous quarter, due to the influence in the year-ago quarter of a large clinical-trial related shipment, that will not be repeated this year.

Net profit for the quarter ended October 31, 2008 was \$337,414 (US\$280,128) or \$0.01 per share compared to a net loss of \$188,174 or (\$0.01) per share for the year-ago quarter. Profit increased by 78% over the previous quarter.

Expenses during the quarter were decreased 63% vs. year-ago and 14% vs. the previous quarter, reflecting the continuing benefits from the 2007 re-organization.



Cash and Working Capital. The Company's Cash, Cash Equivalents, and Marketable Securities increased 7% during the quarter to \$1,676,039.

The Company's working capital was \$2,163,018 as at the end of the first quarter ended October 31, 2008 and up from \$1,832,492 as at the end of the prior quarter ending July 31, 2008.

Financial Summary for the quarters ending

	October 31, 2008	October 31, 2007
Revenues	\$612,430	\$554,887
Earning Before Interests, Tax, Depreciation & Amortization	\$338,165	(\$186,141)
Depreciation, Amortization & Write-Downs	\$15,200	\$16,182
Net Profit (Loss)	\$337,414	(\$188,174)
Profit (Loss) per Share	\$0.01	(\$0.01)
Cash, Cash Equivalents & Marketable Securities	\$1,676,039	\$1,041,472
Working Capital	\$2,163,018	\$1,231,669
Outstanding shares at report date (Common Shares)	24,703,244	24,703,244

INVESTOR RELATIONS

During the quarter IBEX retained the services of Renmark Financial Communications to assist the Company in its investor relations activities. The particulars of the Renmark contract may be found on SEDAR.

LOOKING FORWARD

IBEX has been successful in bringing its existing business to profitability and is now turning its attention to pursuing growth opportunities, including further growing its base business, and maximizing shareholder value through strategic initiatives with companies where increased market strength and synergies might be obtained.

ABOUT IBEX

The Company manufactures and markets a series of proprietary enzymes (heparinases and chondroitinases) for use in pharmaceutical research by our customers, as well Heparinase I, which is used in many leading hemostasis monitoring devices.



IBEX also manufactures and markets a series of arthritis assays which are widely used in pharmaceutical research by our customers. These assays are based on the discovery and increasing role of a number of specific molecular biomarkers associated with collagen synthesis and degradation.

For more information, please visit the Company's web site at www.ibex.ca.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release

###

Safe Harbor Statement

All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which IBEX does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. IBEX disclaims any intention or obligation to update these statements.

Contact:

Paul Baehr
President & CEO
IBEX Technologies Inc.
514-344-4004 x 147

CONSOLIDATED BALANCE SHEETS

	October 31,	July 31,
UNAUDITED	2008	2008
	\$	\$
ASSETS		
Current assets		
Cash and cash equivalents	476,126	372,096
Marketable securities (note 3)	1,199,913	1,195,168
Accounts receivable	611,649	337,621
Inventories	267,873	292,755
Prepaid expenses	49,296	90,206
Sub-total current assets	2,604,857	2,287,846
Property and equipment	248,048	238,809
Total assets	2,852,905	2,526,655
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	441,840	455,354
Total liabilities	441,840	455,354
SHAREHOLDERS' EQUITY		
Capital stock	52,660,078	52,660,078
Contributed surplus	398,602	396,252
Deficit	(50,647,615)	(50,985,029)
Total shareholders' equity	2,411,065	2,071,301
Total liabilities and shareholders' equity	2,852,905	2,526,655
CONSOLIDATED STATEMENTS OF DEFICIT		
	October 31,	October 31,
	2008	2007
	\$	\$
Balance - Beginning of period	(50,985,029)	(51,328,637)
Transition adjustment on adoption of financial instrument standard (note 2)	-	(4,711)
Restated balance - Beginning of period	(50,985,029)	(51,333,348)
Net profit (loss) for the period	337,414	(188,174)
Balance - End of period	(50,647,615)	(51,521,522)

CONSOLIDATED STATEMENTS OF EARNING (LOSS) AND COMPREHENSIVE INCOME (LOSS)

UNAUDITED

For the three months ended October 31st	2008	2007
	\$	\$
Revenue	612,430	554,587
Operating expenses		
Selling, general and administrative expenses and cost of goods sold	(488,910)	(636,730)
Amortization of property and equipment	(15,200)	(16,182)
Other interest and bank charges	(3,078)	(2,011)
Foreign exchange gain (loss)	211,619	(101,987)
Gain on sale of assets	6,104	-
Investment income	14,449	14,149
Total operating expenses	(275,016)	(742,761)
Net profit (loss) and other comprehensive income (loss)	337,414	(188,174)
Net profit (loss) and other comprehensive income (loss) per share		
Basic and diluted	\$ 0.01	\$ (0.01)

See accompanying notes

CONSOLIDATED CASH FLOW STATEMENTS

UNAUDITED

For the three months ended October 31st	2008	2007
	\$	\$
Cash flows provided by (used in):		
Operating activities		
Net profit (loss) for the period	337,414	(188,174)
Items not affecting cash -		
Amortization of property and equipment	15,200	16,182
Stock-based compensation costs	2,351	5,050
Gain on disposal of property and equipment	(6,104)	-
Cash flow relating to operating activities	348,861	(166,942)
Net changes in non-cash working capital items -		
Decrease (increase) in accounts receivable	(274,028)	107,476
Decrease in inventories	24,882	8,004
Decrease in prepaid expenses	40,910	23,354
Decrease in accounts payable and accrued liabilities	(13,514)	(378,845)
Net changes in non-cash working capital balances relating to operations	(221,750)	(240,011)
Cash flow relating to operating activities	127,111	(406,953)
Investing activities		
Additions to marketable securities	(209,207)	-
Proceeds on disposal of marketable securities	204,462	1,099,673
Additions to property and equipment	(24,440)	-
Proceeds on disposal of property and equipment	6,104	-
Cash flow relating to financing activities	(23,081)	1,099,673
Increase in cash and cash equivalents during the quarter	104,030	692,720
Cash and cash equivalents - Beginning of period	372,096	348,752
Cash and cash equivalents - End of period	476,126	1,041,472

Ibex Technologies Inc.
Notes to Consolidated Financial Statements
For the three months ended October 31, 2008 and 2007 (unaudited)

1. Interim financial information

These interim consolidated financial statements do not conform in all respects to the disclosure requirements of Canadian generally accepted accounting principles for annual financial statements and as such the consolidated interim financial statements should be read in conjunction with the annual consolidated financial statements for the years ended July 31, 2008 and 2007, which do conform to the disclosure requirements. These consolidated interim financial statements have been prepared using the same accounting policies as outlined in note 2 to the consolidated financial statements for the years ended July 31, 2008 and 2007 except as outlined in Note 2 below.

The consolidated interim financial statements as at October 31, 2008 and for the three months ended October 31, 2008 are unaudited and have not been reviewed by the company's auditors. The results of operations for these periods are not necessarily indicative of the trends of the operating results for the full year.

2. Accounting Changes

Adoption of New Accounting Pronouncements

During the year ended July 31, 2008, the Company adopted the Canadian Institute of Chartered Accountants ("CICA") Handbook Section 1530, "Comprehensive Income"; Section 3251, "Equity"; Section 3855, "Financial Instruments – Recognition and Measurement"; Section 3862, "Financial Instruments – Disclosures"; Section 3863, "Financial Instruments – Presentation"; and Section 3865, "Hedges". These standards provide accounting guidelines for the recognition, measurement, disclosure and presentation of financial assets, financial liabilities and non-financial derivatives, as well as the introduction of a new statement of comprehensive income. Section 3865 did not have an impact on the Company as it does not use hedge accounting. The Company elected to early adopt Sections 3862 and 3863, as permitted by the standards.

The Company's adoption of these new financial instrument standards resulted in changes in the accounting for financial instruments, as well as the recognition of certain transitional adjustments that have been recorded in opening deficit as described below. The principal changes in the accounting for financial instruments due to the adoption of these accounting standards are as follows.

a) Comprehensive income (loss)

Comprehensive income (loss) is defined as the change in equity from transactions and other events and circumstances from sources other than shareholders, and is composed of the Company's net earnings (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenues, expenses, gains and losses that are recognized in comprehensive income (loss) but excluded from net earnings (loss). The Company does not have any components that qualify as other comprehensive income (loss).

Ibex Technologies Inc.
Notes to Consolidated Financial Statements
For the three months ended October 31, 2008 and 2007 (unaudited)

b) Financial assets and financial liabilities

Financial assets and financial liabilities, including derivatives, are recognized on the consolidated balance sheet when the Company becomes a party to the contractual provisions of the financial instrument or non-financial derivative contract. Financial instruments are initially recognized at fair value and are classified into one of five categories: held for trading, held to maturity, available for sale, loans and receivables, or other financial liabilities. They are subsequently accounted for based on their classification as described below. The classification depends on the purpose for which the financial instruments were acquired and their characteristics. Except in very limited circumstances, the classification is not changed subsequent to initial recognition. Transaction costs are expensed as incurred.

Held for trading

Financial instruments classified as held for trading are carried at fair value at each balance sheet date with the changes in fair value recorded in net earnings (loss) in the period in which the changes arise.

Available for sale

Financial instruments classified as available for sale are carried at fair value at each balance sheet date with the changes in fair value recorded in other comprehensive income (loss) in the period in which the changes arise. Securities that are classified as available for sale and do not have a readily available market value are recorded at cost. Available-for-sale securities are adjusted to fair value through earnings (loss) whenever it is necessary to reflect other than temporary impairment. Upon derecognition, all cumulative gains or losses are then recognized in net earnings (loss).

Held to maturity, loans and receivables, and other financial liabilities

Financial instruments classified as held to maturity, loans and receivables, and other financial liabilities are carried at amortized cost using the effective interest method, and interest income or expense is included in net earnings (loss) over the expected life of the instrument.

Management has selected the following classifications and bases of accounting for the Company's financial instruments:

Asset/Liability	Classification	Basis of accounting
Cash and cash equivalents	Held for trading	Fair value
Marketable securities	Held to maturity	Amortized cost
Accounts receivable	Loans and receivables	Amortized cost
Accounts payable and accrued liabilities	Other financial liabilities	Amortized cost

Ibex Technologies Inc.
Notes to Consolidated Financial Statements
For the three months ended October 31, 2008 and 2007 (unaudited)

c) Embedded derivatives

All derivative instruments are recorded in the consolidated balance sheet at fair value at each balance sheet date. Derivatives may be embedded in other financial instruments (the "host instrument"). Prior to the adoption of the new standards, such embedded derivatives were not accounted for separately from the host instrument. Under the new standards, embedded derivatives are treated as separate derivatives if their economic characteristics and risks are not clearly and closely related to those of the host instrument, the terms of the embedded derivative are the same as those of a stand-alone derivative, and the combined contract is not held for trading or designated at fair value. These embedded derivatives are measured at fair value at each balance sheet date with subsequent changes recognized in net earnings (loss) in the period in which the changes arise. The Company selected August 1, 2002 as its transition date for embedded derivatives, which is the latest date allowed by the accounting standard.

The Company enters into certain contracts for the sale of non-financial items that are denominated in currencies other than the Canadian dollar, the Company's functional currency. In cases where the foreign exchange component is not leveraged, does not contain an option feature and the contract is either denominated in the functional currency of the counterparty, the non-financial item is routinely denominated in the currency of the contract or the currency of the contract is commonly used in the economic environment in which the transaction takes place, the embedded derivative is considered to be closely related and is not accounted for separately. The fair value of financial instruments is determined using recognized valuation models using observable market-based inputs.

Embedded foreign currency derivatives gave rise to a transitional adjustment for the cumulative impact of adopting these new standards for prior years, which was recognized as an adjustment directly to opening deficit of fiscal 2008. No other transitional adjustments were recorded as a result of the adoption of the new standards. The impact of the adoption was a one-time increase of \$4,711 to deficit and accounts payable and accrued liabilities.

During the quarter ended October 31, 2008, the impact of the change in the fair value of the derivatives related to sales contracts is recorded in foreign exchange gain and offset of \$93,310 as at October 31, 2008 is recorded in accounts receivable.

Capital disclosures

During the year ended July 31, 2008, the Company early adopted CICA Handbook Section 1535, "Capital Disclosures", as permitted by the standard. The standard requires the disclosure of both qualitative and quantitative information that enables the users of the financial statements to evaluate the Company's objectives, policies and processes for managing capital.

The adoption of this Section did not have an impact on the Company's financial position, earnings or cash flows; however, it did result in expanded disclosure.

Ibex Technologies Inc.
Notes to Consolidated Financial Statements
For the three months ended October 31, 2008 and 2007 (unaudited)

Inventories

On August 1st, 2008, the Company adopted CICA Handbook section 3031 “Inventories”, which provides guidance on the determination of costs and their subsequent recognition as an expense and provide guidance on the determination of cost, including the allocation of fixed and variable overheads; narrows the permitted costs formulas; and expands the disclosure requirements to increase transparency.

Inventories are composed of work in process and finished goods, which are valued at the lower of cost and net realizable value determined on a first-in, first-out basis. Inventory cost includes materials, direct labour and attributable overhead. During the three months ended October 31, 2008 the Company recognized an expense of \$247,751 in cost of products sold.

	October 31, 2008	July 31, 2008
	\$	\$
Inventories		
Assay kits	\$56,414	\$31,602
Enzymes	\$211,459	\$239,400
Work in process – enzymes	-	\$21,753
	<hr/>	<hr/>
Total inventory	\$267,873	\$292,755
	<hr/>	<hr/>

Goodwill and Intangible Assets

Section 3064 replaces the existing Section 3062, “Goodwill and Other Intangible Assets”, and Section 3450, “Research and Development Costs”. The standard provides guidance on the recognition, measurement and disclosures of goodwill and intangible assets. Management does not expect this Section to have a significant impact on its financial position, earnings or cash flows.

3. Marketable securities

(a) Marketable securities include the following:

	October 31 2008	July 31 2008
	\$	\$
Debt Securities – at cost (which approximates market value (note 2(b)))	1,199,913	1,195,168
	<hr/>	<hr/>
	1,199,913	1,195,168
	<hr/>	<hr/>

(b) The marketable security consists of a discount note which matured on December 1st, 2008 and had an annualized yield of 3.25%.

4. Capital stock and contributed surplus

(a) As at October 31, 2008, the company's authorized capital stock is as follows:

Unlimited as to number

Cumulative, redeemable First preferred shares, issuable in series. The first series consisted of 150,000 shares, convertible into common shares at a rate of 188.68 voting common shares for each preferred share

Cumulative, redeemable convertible Second preferred shares, issuable in series

Third preferred shares, issuable in series

Common shares

(b) Issued

	Book value	
	October 31 2008	July 31 2008
	\$	\$
24,703,244 Common shares (2008-24,703,244)	52,660,078	52,660,078

(c) Stock Options

The company has adopted on August 1, 2004 the fair value based method for accounting for its stock options.

The fair value of the options is estimated as at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

Risk-free interest rate	4.27%
Expected dividend yield	0.00%
Expected life of the options	10 years
Expected volatility	140%

For the three month period ended October 31, 2008, there was an increase to general and administrative expenses of \$2,351 and a corresponding increase to contributed surplus for stock based compensation amortization.

(d) Under the existing IBEX Technologies Inc. ("IBEX") stock option plan, common shares may be issued to full-time employees of the company, directors and consultants, the terms and conditions of grants there under being contingent upon market values, the discretion of the Board of Directors and regulatory requirements. The number of common shares reserved for issuance under this stock option plan is currently

Ibex Technologies Inc.
Notes to Consolidated Financial Statements
For the three months ended October 31, 2008 and 2007 (unaudited)

1,592,992. The maximum term permissible under the plan is 10 years which is determined at the date of grant as well as the vesting privileges.

The following table summarizes the IBEX stock option plan:

	October 31 2008		July 31 2008	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Beginning balance – July 31	1,279,385	\$ 0.28	1,586,668	\$ 0.36
Granted	-	-	325,000	0.10
Expired	-	-	(3,885)	2.55
Cancelled	(30,000)	0.37	(628,398)	0.38
Ending balance	1,249,385	0.29	1,279,385	0.28

The following table summarizes the IBEX stock options outstanding as at October 31, 2008:

Options outstanding				Options currently exercisable	
Range of exercise prices	Number outstanding	Weighted average remaining contractual life (years)	Weighted average exercise price	Number outstanding	Weighted average exercise price
\$			\$		\$
0.06	25,000	9.12	0.06	0	0.00
0.10	280,000	9.41	0.10	150,000	0.10
0.18-0.25	541,500	7.55	0.23	522,500	0.23
0.33-0.45	107,500	4.97	0.40	107,500	0.40
0.50-0.70	295,385	3.26	0.55	295,385	0.55
	1,249,385	7.20	0.29	1,075,385	0.32

(e) Effective February 22, 2008, concurrent with the listing on the TSX Venture Exchange, the IBEX Pharmaceuticals Stock Option Plan was discontinued. The IBEX Technologies Stock Option Plan remains in force.

5. Profit (loss) per share

Profit per share is calculated using the weighted average number of shares outstanding of 24,703,244 (2008 – 24,703,244). Securities which dilute profit per share are employee options. A total of 25,000 options were in the money as of October 31, 2008.

There were no adjustments to the weighted average number of shares outstanding for the purpose of calculating the diluted loss per share for the period ended of October 31, 2008 because to do so would be anti-dilutive.

6. Currency impact

During this quarter, the US dollar strengthened against the Canadian dollar from \$1.024 to \$1.2045. In comparing to the same quarter last year, the US dollar increased an average of 11.7% and based on period ending rates by 27.5%. The increase of the US dollar during the first quarter resulted in the Company recording a gain of \$211,619.

7. Research and Development

Research and development costs are expensed as incurred, unless the development costs meet the generally accepted criteria for deferral. As at October 31, 2008 and July 31, 2008, no such costs have been deferred in the accounts of the Company.